

Paolo Mulatero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5019460/publications.pdf>

Version: 2024-02-01

138
papers

10,698
citations

38720

50
h-index

32815

100
g-index

139
all docs

139
docs citations

139
times ranked

5533
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1045-1050.	1.8	862
2	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	5.5	595
3	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 41-50.	5.5	582
4	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1811-1820.	1.2	520
5	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. <i>Nature Genetics</i> , 2013, 45, 440-444.	9.4	460
6	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4826-4833.	1.8	348
7	Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. <i>Hypertension</i> , 2002, 40, 897-902.	1.3	346
8	Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 454-459.	1.8	340
9	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	1.3	330
10	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2014, 64, 354-361.	1.3	248
11	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 592-598.	1.3	246
12	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. <i>Hypertension</i> , 2012, 59, 235-240.	1.3	176
13	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2618-2623.	1.8	174
14	The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. <i>Endocrine Reviews</i> , 2018, 39, 1057-1088.	8.9	168
15	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2014, 63, 188-195.	1.3	151
16	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1919-1928.	0.3	151
17	Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1366-1371.	1.8	149
18	Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2010, 55, 667-673.	1.3	140

#	ARTICLE	IF	CITATIONS
19	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 296-303.	5.5	134
20	Guidelines for primary aldosteronism. <i>Journal of Hypertension</i> , 2016, 34, 2253-2257.	0.3	134
21	Prevalence and Characteristics of Familial Hyperaldosteronism. <i>Hypertension</i> , 2011, 58, 797-803.	1.3	128
22	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 42-54.	1.8	127
23	Diagnosis of primary aldosteronism: from screening to subtype differentiation. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 114-119.	3.1	125
24	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2573-2575.	1.8	121
25	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. <i>Molecular and Cellular Endocrinology</i> , 2015, 411, 146-154.	1.6	115
26	Diagnosis and treatment of primary aldosteronism. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 876-892.	5.5	106
27	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 881-889.	1.8	105
28	Role of KCNJ5 in familial and sporadic primary aldosteronism. <i>Nature Reviews Endocrinology</i> , 2013, 9, 104-112.	4.3	101
29	Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism. <i>Clinical Chemistry</i> , 2007, 53, 1968-1971.	1.5	95
30	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	1.3	94
31	Psychological Assessment of Primary Aldosteronism: A Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E878-E883.	1.8	91
32	Diagnosis and treatment of low-renin hypertension. <i>Clinical Endocrinology</i> , 2007, 67, 324-334.	1.2	89
33	The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. <i>Nature Structural and Molecular Biology</i> , 1997, 4, 32-35.	3.6	88
34	Effect of Adrenocorticotrophic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 840-846.	1.3	87
35	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1861-E1865.	1.8	86
36	Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. <i>Journal of Hypertension</i> , 2008, 26, 1577-1582.	0.3	82

#	ARTICLE	IF	CITATIONS
37	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	1.3	77
38	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1929-1936.	0.3	74
39	CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism. <i>Hypertension</i> , 2000, 35, 694-698.	1.3	72
40	Liddle Syndrome: Review of the Literature and Description of a New Case. <i>International Journal of Molecular Sciences</i> , 2018, 19, 812.	1.8	69
41	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100029.	2.2	69
42	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3187-3191.	1.8	67
43	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Annals of Surgery</i> , 2020, 272, 1125-1132.	2.1	66
44	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With <i>KCNJ5</i> Mutations and Protects From Calcium-Induced Apoptosis. <i>Hypertension</i> , 2012, 59, 833-839.	1.3	64
45	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. <i>Hypertension</i> , 2016, 67, 146-152.	1.3	63
46	Renal damage in primary aldosteronism. <i>Journal of Hypertension</i> , 2020, 38, 3-12.	0.3	63
47	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4158-4166.	1.8	62
48	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. <i>Journal of Hypertension</i> , 2016, 34, 920-927.	0.3	61
49	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. <i>Hypertension</i> , 2020, 75, 1025-1033.	1.3	60
50	Captopril Test Can Give Misleading Results in Patients With Suspect Primary Aldosteronism. <i>Hypertension</i> , 2007, 50, e26-7.	1.3	55
51	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E114-E118.	1.8	53
52	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. <i>JAMA Network Open</i> , 2020, 3, e2016209.	2.8	53
53	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	1.3	51
54	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. <i>Journal of Hypertension</i> , 2011, 29, 1773-1777.	0.3	50

#	ARTICLE	IF	CITATIONS
55	Is Primary Aldosteronism Still Largely Unrecognized?. <i>Hormone and Metabolic Research</i> , 2017, 49, 908-914.	0.7	50
56	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , 2014, 394, 13-20.	1.6	48
57	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3706-e3717.	1.8	47
58	1 α -Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes. <i>Hypertension</i> , 1999, 33, 708-712.	1.3	46
59	Differential diagnosis of primary aldosteronism subtypes. <i>Current Hypertension Reports</i> , 2009, 11, 217-223.	1.5	46
60	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. <i>European Journal of Endocrinology</i> , 2018, 178, R101-R111.	1.9	46
61	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 311-320.	1.6	45
62	Primary Aldosteronism and Obstructive Sleep Apnea. <i>Hypertension</i> , 2019, 74, 1532-1540.	1.3	45
63	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. <i>Hypertension</i> , 2010, 55, 1468-1475.	1.3	43
64	Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2006, 4, 75-91.	0.4	40
65	Is There a Role for Genomics in the Management of Hypertension?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1131.	1.8	40
66	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 848.	1.8	40
67	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 535-541.	1.4	39
68	Deletion Hybrid Genes, due to Unequal Crossing Over between <i>CYP11B1</i> (11 β -Hydroxylase) and <i>CYP11B2</i> (Aldosterone Synthase) Cause Steroid 11 β -Hydroxylase Deficiency and Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3197-3201.	1.8	38
69	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 105-108.	1.0	37
70	<i>KCNJ5</i> Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. <i>Hypertension</i> , 2015, 65, 507-509.	1.3	34
71	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. <i>Kidney International</i> , 2005, 67, 631-637.	2.6	33
72	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 279-285.	1.4	33

#	ARTICLE	IF	CITATIONS
73	The SPARTACUS Trial: Controversies and Unresolved Issues. <i>Hormone and Metabolic Research</i> , 2017, 49, 936-942.	0.7	33
74	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. <i>Hypertension</i> , 2020, 75, 163-172.	1.3	33
75	Diagnostic approach to low-renin hypertension. <i>Clinical Endocrinology</i> , 2018, 89, 385-396.	1.2	32
76	Mutation affecting the conserved acidic WNK1 motif causes inherited hyperkalemic hyperchloremic acidosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 6379-6394.	3.9	32
77	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B ₂ Receptor and Î±-Adducin Gene Polymorphisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3337-3343.	1.8	30
78	Diagnosis and treatment of primary aldosteronism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2011, 12, 3-9.	2.6	30
79	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e282-e289.	1.8	29
80	Genetics of primary aldosteronism. <i>Journal of Hypertension</i> , 2004, 22, 663-670.	0.3	28
81	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 274-282.	1.2	28
82	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. <i>Pharmacogenomics</i> , 2014, 15, 1643-1652.	0.6	27
83	1Î±,25-Dihydroxyvitamin D ₃ inhibits the human H295R cell proliferation by cell cycle arrest: A model for a protective role of vitamin D receptor against adrenocortical cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 140, 26-33.	1.2	26
84	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. <i>Hypertension Research</i> , 2020, 43, 500-510.	1.5	26
85	QT interval in patients with primary aldosteronism and low-renin essential hypertension. <i>Journal of Hypertension</i> , 2006, 24, 2459-2464.	0.3	25
86	Adrenal Venous Samplingâ€“Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1400-e1407.	1.8	25
87	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. <i>Endocrine Journal</i> , 2012, 59, 497-502.	0.7	24
88	Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology. <i>Endocrinology</i> , 2017, 158, 4129-4138.	1.4	24
89	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 359-367.	1.3	23
90	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. <i>Endocrine</i> , 2017, 58, 503-512.	1.1	22

#	ARTICLE	IF	CITATIONS
91	Evaluation of primary aldosteronism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 188-193.	1.2	21
92	Aldosterone effects on glomerular structure and function. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 730-738.	1.0	20
93	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4382-e4392.	1.8	20
94	A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 82, 83-88.	1.2	19
95	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1128.	1.8	19
96	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. <i>Molecular and Cellular Endocrinology</i> , 2012, 355, 162-168.	1.6	18
97	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	1.8	17
98	The spectrum of low-renin hypertension. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101399.	2.2	17
99	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3655-e3664.	1.8	16
100	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1708-1716.	1.8	16
101	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. <i>Liver</i> , 1998, 18, 420-426.	0.1	15
102	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. <i>Hypertension</i> , 2011, 57, 1053-1055.	1.3	15
103	10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. <i>Journal of Hypertension</i> , 2019, 37, 603-611.	0.3	14
104	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. <i>Hormone and Metabolic Research</i> , 2020, 52, 366-372.	0.7	14
105	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 78, 726-737.	1.3	14
106	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. , 0, .		14
107	Primary aldosteronism in the primary care setting. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 155-159.	1.2	12
108	Primary Aldosteronism in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2320-e2326.	1.8	12

#	ARTICLE	IF	CITATIONS
109	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. <i>Hypertension</i> , 2015, 66, 248-253.	1.3	10
110	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. <i>Hypertension</i> , 2021, 78, 1595-1604.	1.3	10
111	Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtype-Specific Alterations. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800049.	0.8	9
112	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. <i>Current Hypertension Reviews</i> , 2013, 9, 156-165.	0.5	9
113	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 353-359.	1.0	9
114	Primary aldosteronism in pregnancy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 39-48.	2.6	9
115	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. <i>Hypertension</i> , 2021, 77, 1647-1658.	1.3	8
116	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. <i>European Journal of Endocrinology</i> , 2020, 183, 657-667.	1.9	8
117	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. <i>Translational Research</i> , 2022, , .	2.2	8
118	Quality of life in primary aldosteronism: A prospective observational study. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13419.	1.7	7
119	Hypertension, genotype and oral contraceptives. <i>Pharmacogenomics</i> , 2002, 3, 57-63.	0.6	6
120	Aldosterone as an Independent Factor in Cerebrovascular Damage. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 785-797.	0.5	6
121	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 94, 29-35.	0.3	6
122	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1675.	1.8	5
123	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1262-E1269.	1.8	4
124	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2020, 22, H70-H73.	0.0	4
125	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2021, 23, B77-B81.	0.0	4
126	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 203-208.	1.0	3

#	ARTICLE	IF	CITATIONS
127	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. Journal of the Endocrine Society, 2017, 1, 401-406.	0.1	3
128	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 121-125.	1.0	2
129	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. Endocrine, 2016, 54, 826-829.	1.1	2
130	Ca ²⁺ channels of the L-type in peripheral blood lymphocytes of essential hypertensives. American Journal of Hypertension, 1999, 12, 40-46.	1.0	1
131	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. Hypertension, 2016, 67, e3-4.	1.3	1
132	Genetics of Familial Hyperaldosteronism. , 2019, , 623-630.		1
133	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	1.0	0
134	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	1.0	0
135	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	1.0	0
136	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. Frontiers in Pharmacology, 2021, 12, 668843.	1.6	0
137	Response to Letter to the Editor from Rossi and Rossitto: "Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism". Journal of Clinical Endocrinology and Metabolism, 2022, 107, e896-e897.	1.8	0
138	SUN-LB97 Targeted Metabolomics as a Screening Tool in the Diagnosis of Endocrine Hypertension. Journal of the Endocrine Society, 2020, 4, .	0.1	0